When the World Health Organization (WHO) updates its Model List of Essential Medicines (EML), it gives governments a ...
Belgian life sciences company SpectaCell has launched with 6 million euros ($6.7 million) in seed financing to develop a cell ...
The US Food and Drug Administration (FDA) has approved oche’s Tecentriq atezolizumab) and Tecentriq Hybreza (atezolizumab and ...
Biohub, the nonprofit research institute combining AI and biology, has joined the US Department of Energy (DOE), the National ...
US pharma major Bristol Myers Squibb said its Phase III EXCALIBER-RRMM trial met its progression-free survival (PFS) endpoint ...
Japanese drugmaker Shionogi and Ceolia Pharma have entered into an agreement regarding the transfer of the marketing ...
USA-based companies Viatris and Pacira BioSciences have entered into a definitive agreement under which Viatris has agreed to ...
Privately-held US biopharma Cerevance said its Phase III ARISE trial of once-daily oral solengepras met its primary endpoint ...
US rare diseases specialist Ultragenyx Pharmaceutical announced it has entered into a definitive agreement to sell a Rare ...
Italian neuroscience company Newron Pharmaceuticals has set out the US Food and Drug Administration's (FDA) reasons for the ...
The US Food and Drug Administration (FDA) approved Swiss pharma giant Novartis’ Rhapsido (remibrutinib), an oral, highly selective Bruton’s tyrosine kinase inhibitor (BTKi), as the first treatment for ...
Japan’s Ono Pharmaceutical today announced that it has entered into an exclusive license agreement with US biopharma Biohaven for the development and commercialization of Biohaven’s IgG degrader ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results